Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2013

01-10-2013 | Research Article

Blood concentrations of cefuroxime in cardiopulmonary bypass surgery

Authors: Daphne Bertholee, Peter G. J. ter Horst, Michel L. Hijmering, Alexander J. Spanjersberg, Wobbe Hospes, Bob Wilffert

Published in: International Journal of Clinical Pharmacy | Issue 5/2013

Login to get access

Abstract

Objectives Patients with coronary artery bypass graft (CABG) surgery are at risk for severe postoperative infections. Prophylactic cefuroxime may help to reduce this risk, however sufficient concentrations, i.e. above the breakpoint (32 mg/L), are mandatory. The aim of this study is to evaluate the blood concentrations of cefuroxime during and after CABG surgery with cardiopulmonary bypass (CPB) and hypothermia, to determine the concentration of cefuroxime in sternum fluid and to evaluate possible factors of influence. Methods Seventeen patients were enrolled in this study, given 1.5 g cefuroxime at anaesthesia induction and an additional 1.5 g at start CPB. Blood samples were collected at skin incision, start CPB, every 30 min on CPB, end CPB, at wound closure and 1 h after surgery. Cefuroxime concentrations were determined by high performance liquid chromatography. Results In 47 % of the patients the cefuroxime concentration was below the breakpoint at some point during the operation and in 59 % of the patients 1 h after surgery. A statistically significant inverse correlation between estimated glomerular filtration rate and plasma cefuroxime concentrations was found (P = 0.034). Cefuroxime levels in the sternum are not significantly different from blood levels from the radial artery catheter, taken at approximately the same time (P = 0.30). Conclusions The current antibiotic regimen used did not maintain cefuroxime concentrations above the breakpoint throughout the operation, suggesting insufficient antibiotic prophylaxis. Further research to other antibiotic regimes is therefore necessary.
Literature
1.
go back to reference Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention project. Am J Surg. 2005;189:395–404.PubMedCrossRef Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention project. Am J Surg. 2005;189:395–404.PubMedCrossRef
2.
go back to reference Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg. 2006;81:397–404.PubMedCrossRef Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg. 2006;81:397–404.PubMedCrossRef
3.
4.
go back to reference Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg. 2001;20:1168–75.PubMedCrossRef Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg. 2001;20:1168–75.PubMedCrossRef
5.
go back to reference De Feo M, Renzulli A, Ismeno G, Gregorio R, la Corte A, Utili R, et al. Variables predicting adverse outcome in patients with deep sternal wound infection. Ann Thorac Surg. 2001;71:324–31.PubMedCrossRef De Feo M, Renzulli A, Ismeno G, Gregorio R, la Corte A, Utili R, et al. Variables predicting adverse outcome in patients with deep sternal wound infection. Ann Thorac Surg. 2001;71:324–31.PubMedCrossRef
6.
go back to reference Gardlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery—microbiology and pathogenesis. Eur J Cardiothorac Surg. 2002;21:825–30.PubMedCrossRef Gardlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery—microbiology and pathogenesis. Eur J Cardiothorac Surg. 2002;21:825–30.PubMedCrossRef
7.
go back to reference Kriaras I, Michalopoulos A, Turina M, Geroulanos S. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardiothorac Surg. 2000;18:440–6.PubMedCrossRef Kriaras I, Michalopoulos A, Turina M, Geroulanos S. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardiothorac Surg. 2000;18:440–6.PubMedCrossRef
8.
go back to reference Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention project. Clin Infect Dis. 2004;38:1706–15.PubMedCrossRef Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention project. Clin Infect Dis. 2004;38:1706–15.PubMedCrossRef
9.
go back to reference Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. AJHP. 2013;70(3):195–283.PubMed Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. AJHP. 2013;70(3):195–283.PubMed
10.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard. Ed 10 document M100–S20; 2010. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard. Ed 10 document M100–S20; 2010.
11.
go back to reference European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST breakpoint table version 3.1. Availble at http://www.eucast.org. Last accessed 4 June 2013. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST breakpoint table version 3.1. Availble at http://​www.​eucast.​org. Last accessed 4 June 2013.
12.
go back to reference Viberg A, Cars O, Karlsson MO, Jonsson S. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. J Clin Pharmacol. 2008;48:1270–81.PubMedCrossRef Viberg A, Cars O, Karlsson MO, Jonsson S. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. J Clin Pharmacol. 2008;48:1270–81.PubMedCrossRef
13.
go back to reference Flynn Pharma Ltd. Summary of product characteristics cefuroxime; 2009. Flynn Pharma Ltd. Summary of product characteristics cefuroxime; 2009.
14.
go back to reference Smith BR, LeFrock JL. Cefuroxime: Antimicrobial activity, pharmacology, and clinical efficacy. [review]. Ther Drug Monit. 1983;5(2):149–60.PubMedCrossRef Smith BR, LeFrock JL. Cefuroxime: Antimicrobial activity, pharmacology, and clinical efficacy. [review]. Ther Drug Monit. 1983;5(2):149–60.PubMedCrossRef
15.
16.
go back to reference Nascimento JWL, Carmona MJC, Strabelli TMV, Auler JOC Jr, Santos SRCJ. Perioperative cefuroxime pharmacokinetics in cardiac surgery. Clinics. 2007;62(3):257–60.PubMedCrossRef Nascimento JWL, Carmona MJC, Strabelli TMV, Auler JOC Jr, Santos SRCJ. Perioperative cefuroxime pharmacokinetics in cardiac surgery. Clinics. 2007;62(3):257–60.PubMedCrossRef
17.
go back to reference Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000;44:261–73.PubMedCrossRef Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000;44:261–73.PubMedCrossRef
18.
go back to reference Hsu LC. Biocompatibility in cardiopulmonary bypass. J Cardiothorac and Vasc Anesth. 1997;11:376–82.CrossRef Hsu LC. Biocompatibility in cardiopulmonary bypass. J Cardiothorac and Vasc Anesth. 1997;11:376–82.CrossRef
19.
go back to reference Milic R, Colombini A, Lombardi G, Lanteri P, Banfi G. Estimation of glomerular filtration rate by MDRD equation in athletes: role of body surface area. Eur J Appl Physiol. 2012;112(1):201–6.PubMedCrossRef Milic R, Colombini A, Lombardi G, Lanteri P, Banfi G. Estimation of glomerular filtration rate by MDRD equation in athletes: role of body surface area. Eur J Appl Physiol. 2012;112(1):201–6.PubMedCrossRef
20.
go back to reference Braxton JH, Marrin CA, McGrath PD, Morton JR, Norotsky M, Charlesworth DC, et al. 10-year follow-up of patients with and without mediastinitis. Semin Thorac Cardiovasc Surg. 2004;16:70–6.PubMedCrossRef Braxton JH, Marrin CA, McGrath PD, Morton JR, Norotsky M, Charlesworth DC, et al. 10-year follow-up of patients with and without mediastinitis. Semin Thorac Cardiovasc Surg. 2004;16:70–6.PubMedCrossRef
21.
go back to reference Nascimento JWL, Carmona MJC, Strabelli TMV, Auler J, Santos SRCJ. Systemic availability of prophylactic cefuroxime in patients submitted to coronary artery bypass grafting with cardiopulmonary bypass. J Hosp Infect. 2005;59:299–303.PubMedCrossRef Nascimento JWL, Carmona MJC, Strabelli TMV, Auler J, Santos SRCJ. Systemic availability of prophylactic cefuroxime in patients submitted to coronary artery bypass grafting with cardiopulmonary bypass. J Hosp Infect. 2005;59:299–303.PubMedCrossRef
22.
go back to reference Mandak J, Pojar M, Malakova J, Lonsky V, Palicka V, Zivny P. Tissue and plasma concentrations of cephuroxime during cardiac surgery in cardiopulmonary bypass—microdialysis study. Perfusion. 2007;22:129–36.CrossRef Mandak J, Pojar M, Malakova J, Lonsky V, Palicka V, Zivny P. Tissue and plasma concentrations of cephuroxime during cardiac surgery in cardiopulmonary bypass—microdialysis study. Perfusion. 2007;22:129–36.CrossRef
23.
go back to reference Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 2002;19:285–90.PubMedCrossRef Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 2002;19:285–90.PubMedCrossRef
24.
go back to reference Pojar M, Mandak J, Malakova J, Jokesova I. Tissue and plasma concentrations of antibiotic during cardiac surgery with cardiopulmonary bypass- microdialysis study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:139–45.PubMedCrossRef Pojar M, Mandak J, Malakova J, Jokesova I. Tissue and plasma concentrations of antibiotic during cardiac surgery with cardiopulmonary bypass- microdialysis study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:139–45.PubMedCrossRef
25.
go back to reference Mouton J, Vinks A. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5–15.PubMedCrossRef Mouton J, Vinks A. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5–15.PubMedCrossRef
26.
go back to reference Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996;40:61–4.PubMed Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996;40:61–4.PubMed
Metadata
Title
Blood concentrations of cefuroxime in cardiopulmonary bypass surgery
Authors
Daphne Bertholee
Peter G. J. ter Horst
Michel L. Hijmering
Alexander J. Spanjersberg
Wobbe Hospes
Bob Wilffert
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9810-z

Other articles of this Issue 5/2013

International Journal of Clinical Pharmacy 5/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.